Literature DB >> 2893361

Mu-opiate binding and morphine antagonism by octapeptide analogs of somatostatin.

J M Walker1, W D Bowen, S T Atkins, M K Hemstreet, D H Coy.   

Abstract

A series of cyclic conformationally restrained octapeptide analogs of somatostatin were examined for their ability to inhibit the binding of tritiated mu, kappa, and delta opiate receptor ligands. Several of these substances were found to have high affinity for mu opiate receptors while having very low affinity for both kappa and delta receptors. Previous suggestions that somatostatin analogs exhibit opiate antagonist activity led to a study of the ability of the two most potent compounds to inhibit morphine analgesia in rats after intracerebroventricular injection. One of the compounds significantly antagonized morphine analgesia although the other displayed severe toxicity. These two compounds differed in that the very toxic compound had previously been found to possess significant somatostatin activity. It thus appears that the structural requirements for toxicity and somatostatin activity can be differentiated from those for opiate activity.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2893361     DOI: 10.1016/0196-9781(87)90074-x

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  4 in total

1.  Pharmacokinetic study and effects on growth hormone secretion in healthy volunteers of the new somatostatin analogue BIM 23014.

Authors:  J M Kuhn; C Basin; M Mollard; B de Rougé; C Baudoin; R Obach; G Tolis
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

2.  Pharmacokinetic and pharmacodynamic properties of a long-acting formulation of the new somatostatin analogue, lanreotide, in normal healthy volunteers.

Authors:  J M Kuhn; A Legrand; J M Ruiz; R Obach; J De Ronzan; F Thomas
Journal:  Br J Clin Pharmacol       Date:  1994-09       Impact factor: 4.335

3.  Sex-dependent modulation of treatment response.

Authors:  David R Rubinow; Molly Moore
Journal:  Dialogues Clin Neurosci       Date:  2004-03       Impact factor: 5.986

4.  δ-opioid receptor and somatostatin receptor-4 heterodimerization: possible implications in modulation of pain associated signaling.

Authors:  Rishi K Somvanshi; Ujendra Kumar
Journal:  PLoS One       Date:  2014-01-08       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.